Divi’s Laboratories Q2 Results FY27: 7 Nov Date, Profit Base

Earnings · Divi’s Laboratories Limited

Divi’s Laboratories is listed to report its September-quarter numbers on 7 November 2026. Here are the date check, the strong profit base, the Q1 jump, the margin and income lines that sources report differently, and the figures to read first.

Updated: Sunday, 1 November 2026, 11:15 AM IST  |  Reading time: 19 min  |  Next update: Saturday, 7 November 2026, after the exchange filing

Latest update (Sunday, 1 November 2026, 11:15 AM IST): The results are not out. Kotak Neo’s weekly list shows Divi’s Laboratories for Saturday, 7 November; the date rests on that one report and the filing time is not announced. This page becomes the live analysis after the filing.

Earlier entries:

• Friday, 30 October 2026, 6:00 PM IST: Kotak Neo listed Divi’s Laboratories among Saturday’s results.
• Saturday, 1 August 2026: Q1 FY27 results were announced, per Angel One.

In plain words: Before the Divi’s Laboratories Q2 results arrive, remember that the company makes the active ingredients and intermediates that other drug companies use. Its profit depends on orders, product mix and the exchange rate, because much of its income is in dollars. A preview tells you which figures to hold the new numbers against.

Data note: Figures are as of Sunday, 1 November 2026, 11:15 AM IST. The results date comes from one weekly list; the filing itself was not opened for this page. Base figures are company results as reported by Business Today, Kotak Neo, Angel One and Sahi. Derived numbers are my calculation.

When are the Divi’s Laboratories Q2 results?

The Divi’s Laboratories Q2 results date is listed as Saturday, 7 November 2026. The date rests on one weekly list, so confirm it on the exchange page.

Kotak Neo’s weekly list, posted at 6:00 PM IST on 30 October 2026, names Divi’s Laboratories among Saturday’s results, and says dates are based on announced board-meeting schedules and may change. I found no second report that quotes the intimation, so treat the date as likely but unconfirmed.

Last year the company reported its Q2 FY26 numbers on Friday, 7 November 2025, and Q1 FY27 came on a Saturday, 1 August 2026, per Angel One, so a weekend date fits its pattern. The filing time is not announced. Do not trust a screenshot that claims a time before the exchange page shows it.

What will Divi’s Laboratories publish?

Divi’s Laboratories will publish unaudited consolidated and standalone results for the quarter and half-year ended 30 September 2026. It reports one segment, manufacturing active pharmaceutical ingredients, intermediates and nutraceutical ingredients, so the filing has no segment table to read. The foreign-exchange line and the notes carry the extra detail.

Is the date confirmed?

Cite this table: PositionalCalls, “Divi’s Laboratories Q2 FY27 Date Check, as of 1 November 2026”.

Treat any article that gives another date for the Divi’s Laboratories Q2 results as unreliable until you see the filing.

What is the base to beat for the Divi’s Laboratories Q2 results?

The base to beat is Q2 FY26 profit of Rs 689 crore on revenue from operations of Rs 2,715 crore, against Rs 902 crore and Rs 3,080 crore in Q1 FY27.

Cite this table: PositionalCalls, “Divi’s Laboratories Base-to-Beat Table, as of 1 November 2026”.

Divi’s Laboratories EBITDA Q2 FY27: the flat-quarter sum

Here is the first useful sum. Q1 FY27 revenue from operations of Rs 3,080 crore is +13.4% above Q2 FY26’s Rs 2,715 crore, total income is +9.9% above Rs 2,860 crore, and net profit of Rs 902 crore is +30.9% above Rs 689 crore (my calculations). A flat Q2 would therefore still show strong year-on-year growth, which is why the bar is the Q1 level and not last year’s.

How was the Q2 FY26 base built?

Business Today reported profit before tax of Rs 912 crore against Rs 722 crore a year earlier, with forex gains of Rs 63 crore against Rs 29 crore. First-half FY26 profit after tax was Rs 1,234 crore, up from Rs 940 crore. The shares still fell 3.85% on results day to a low of Rs 6,621.50, which shows a strong quarter does not guarantee a rise.

Divi’s Laboratories Q2 results preview: what to expect

No consensus estimate was found for Q2 FY27. The preview rests on the base figures and on the size of the Q1 FY27 jump.

Cite this table: PositionalCalls, “Divi’s Laboratories Q2 FY27 Q1 Marks, as of 1 November 2026”.

Last year the company grew from Q1 to Q2: total income rose 13.1% (2,529 to 2,860) and profit rose 26.4% (545 to 689, my calculations). A repeat of that sequential pattern is not guaranteed, because orders and product mix move from quarter to quarter.

Divi’s Laboratories net profit Q2 FY27: what to expect

Q1 FY27 profit before tax was Rs 1,180 crore against Rs 912 crore in Q2 FY26, a gap of Rs 268 crore (my calculation), while the tax rate was about 23.6% (278 divided by 1,180). The Q1 tax rate and the swing from a Rs 63 crore forex gain to a Rs 7 crore loss are the two items that move profit without a change in sales.

How did the shares react to Q1?

Angel One reported the NSE close on 31 July 2026 at Rs 8,056, up 2.82%, the day before the results, and a headline that shares rose over 3% after the numbers. That was a reaction to what the market expected, not a forecast of Q2 FY27, and it says nothing about what the filing will show.

Divi’s Laboratories EBITDA and profit Q2 FY27: scenarios

These Divi’s Laboratories Q2 results scenarios are arithmetic, not forecasts. A flat Q1 profit would be +30.9% on Q2 FY26.

Assumptions: consolidated; Q2 FY26 revenue from operations Rs 2,715 crore; revenue growth of 15%, 20% and 25% is my illustration around the Q1 FY27 growth of 27.8%; EBITDA margins of 38.0%, 40.75% and 43.0% bracket the Q1 figures of 40.75% (Sahi) and about 42.8% (my calculation on revenue from operations).

Cite this table: PositionalCalls, “Divi’s Laboratories Q2 FY27 EBITDA Scenarios, as of 1 November 2026”.

Profit scenarios

Cite this table: PositionalCalls, “Divi’s Laboratories Q2 FY27 Profit Scenarios, as of 1 November 2026”.

Three worked examples

• Q1-like profit: profit +31% is Rs 903 crore, about flat on Q1 FY27’s Rs 902 crore (689 times 1.31, my calculation).
• Revenue +20%: Rs 3,258 crore, and a 40.75% margin gives EBITDA of Rs 1,328 crore (my calculation).
• Slower profit growth: +20% is Rs 827 crore, which would be -8% on Q1 FY27 even though it is still growth on last year.

The scenarios hold other lines constant. In practice depreciation, tax, other income and the exchange rate sit between EBITDA and profit, and the company has said little about the timing of orders.

Which Divi’s Laboratories figures should you compare?

When you compare the Divi’s Laboratories Q2 results with last year, match revenue from operations with revenue from operations, and total income with total income. Figures appear on both bases.

Cite this table: PositionalCalls, “Divi’s Laboratories Definition-Trap Table, as of 1 November 2026”.

The Q1 FY27 net margin shows the same issue: 902 divided by 3,144 is 28.7% and 902 divided by 3,080 is 29.3% (my calculations). Neither is wrong; they use different denominators. Write down which one a headline uses.

The same care applies to growth rates. Sahi gives Q1 FY27 revenue from operations up 27.8% from Rs 2,410 crore, while Angel One and Kotak Neo give total income up 24.3% from Rs 2,529 crore. An article that mixes Rs 3,144 crore with the 27.8% rate is quoting two different measures, so recompute the rate from the figures if you are unsure which was used.

EBITDA versus profit

EBITDA is earnings before interest, tax, depreciation and amortisation. The gap between EBITDA and profit is made of depreciation, finance cost, tax and other income, and forex gains or losses sit inside other income.

The estimate base trap

A growth rate applied to Rs 689 crore and to a different base gives two different profits. Check which line and which quarter an estimate uses before you compare it with the table above.

What do forex and mix need to show?

In the Divi’s Laboratories Q2 results the exchange line may matter again: it swung from a Rs 39 crore gain to a Rs 7 crore loss between Q1 FY26 and Q1 FY27, so read operating profit and the forex line separately.

Cite this table: PositionalCalls, “Divi’s Laboratories Forex and Cost Marks, as of 1 November 2026”.

In Q1 FY27, total income rose 24.3% while total expenses rose only 9.4% (my reading of Kotak Neo’s table), which explains the profit before tax rise of 61.0%. Watch whether expenses stay low against income in Q2.

Custom synthesis, the made-to-order part of the business, was credited for the Q2 FY26 EBITDA beat in a PL Capital note, which also expected margins to improve on mix. That is one brokerage view and not a company statement.

Which other results land the same week as Divi’s Laboratories?

Kotak Neo’s weekly list shows Hindalco, Bosch and TTK Prestige on Friday, and Apollo Hospitals, Dabur and BSE on Wednesday.

The list is partial and dates may change. For the format of a results read, see our recent posts on Apollo Hospitals Q2 results, Berger Paints Q2 results and Marico Q2 results. They cover other companies, so only the method carries over. The Q2 results calendar and the earnings calendar list the companies that have reported.

If you hold Divi’s shares and plan to sell later, our guide to capital gains tax on shares covers how gains are taxed. It is general information, not tax advice.

How to read the Divi’s Laboratories Q2 results in 10 minutes

To read the Divi’s Laboratories Q2 results quickly, go through seven lines in order: revenue from operations, total income, EBITDA, profit before tax, forex, net profit and the notes.

Cite this table: PositionalCalls, “Divi’s Laboratories Results-Day Decoder, as of 1 November 2026”.

How to read the Divi’s Laboratories filing on NSE or BSE

Open the exchange announcement, find the consolidated statement and compare each line with the base table above, same measure, same basis.

1. Open the BSE corporate announcements page or the NSE corporate filings page and search for Divi’s Laboratories.
2. Choose the financial results announcement for the quarter ended 30 September 2026.
3. Find the consolidated statement first, then the standalone.
4. Check the unit and whether a column is for the quarter or six months.
5. Read revenue from operations, other income, total income and profit before tax.
6. Find the foreign-exchange gain or loss in the notes or other income.
7. Check the notes for exceptional items.
8. Compare every figure with the base table.

What it costs: reading a filing is free. If you trade the stock, brokerage, securities transaction tax and other charges apply, so check your broker’s current schedule. Tax angle: dividends and gains follow the current tax rules, so see our guide to capital gains tax on shares or ask a tax adviser. Scam warning: on results day, fake “result alert” groups and sure-shot tips circulate. Nobody can guarantee a gain, and official filings are free.

What is the results-day checklist for Divi’s Laboratories?

• Confirm the date on the BSE or NSE announcement page.
• Note the filing time and stamp what you read with it.
• Open the consolidated statement of the Divi’s Laboratories Q2 results before any headline.
• Compare revenue from operations with Rs 2,715 crore and Rs 3,080 crore.
• Check whether a figure is total income or revenue from operations.
• Compare net profit with Rs 689 crore and Rs 902 crore.
• Find the forex gain or loss.
• Check the notes for one-off items.
• Write your own plan before the price moves.

What are the risks around the Divi’s Laboratories Q2 results?

How to grade Divi’s Laboratories’s September-quarter numbers: a reading guide

Use the table to grade the Divi’s Laboratories Q2 results as a reading aid, not a forecast. The cut-offs are my illustration, built from the Q1 FY27 marks.

Assumptions: Q2 FY26 revenue from operations Rs 2,715 crore and net profit Rs 689 crore; the Q1 FY27 profit of Rs 902 crore is the strong mark.

Cite this table: PositionalCalls, “Divi’s Laboratories Q2 FY27 Reading Guide, as of 1 November 2026”.

Worked example: suppose revenue from operations is Rs 3,300 crore and net profit Rs 880 crore. Revenue would be up +21.5% (3,300 divided by 2,715), profit up +27.7% on Rs 689 crore and -2.4% on Q1 FY27 (my calculation). Revenue would read stronger and profit in line, with a small sequential dip that is easy to mistake for weakness when year-on-year growth is large.

A strong reading describes the quarter only. It is not a signal to buy, sell or hold, and a weak one is not a signal either. Prices react to many things, including what the market already expected.

The guide to the Divi’s Laboratories Q2 results uses consolidated figures throughout. If a headline quotes standalone profit, compare it with the standalone base and say so when you share the number. Mixing the two is a common error on results day, because the company reports both.

What do most people miss on Divi’s Laboratories results day?

Analyst’s note: how to think about this quarter

Part of the earnings coverage, including pharma results.

Divi’s Laboratories Q2 results: frequently asked questions

Sources

• BSE corporate announcements: where the Divi’s Laboratories filing appears.
• NSE corporate filings: financial results: the same filing on NSE.
• Kotak Neo: Q2 results this week, 30 October 2026.
• Kotak Neo: Divi’s Laboratories Q1 FY27 results, August 2026.
• Angel One: Divi’s Laboratories Q1 FY27, 1 August 2026.
• Sahi: Divi’s Laboratories Q1 FY27 results, August 2026.
• Business Today: Divi’s Labs Q2 FY26 results, 7 November 2025.
• PL Capital: Divi’s Laboratories Q2 FY26 result update, November 2025.

Disclosure: PositionalCalls.com is not a SEBI-registered research analyst or investment adviser. Investments in securities markets are subject to market risks. Read all related documents carefully before investing. Returns are never guaranteed. PositionalCalls is an independent research and education site founded by Shubham Chaudhary. Nothing here is a recommendation, target or investment advice. How I researched this: I checked the results date in one weekly list, took base figures from company results as reported by Business Today, Kotak Neo, Angel One and Sahi, noted where sources differ, and marked every derived number as my calculation. Figures are as of Sunday, 1 November 2026, 11:15 AM IST.